BDAZ, thanks for the remarkable posts and insights.

This all seems to be very good news going forward. The July 27 filing is a clear demonstration of their significant achievements and gives us a clear understanding of the situation including the FDA.........which seems very hopeful.

Your reference to p14 with MACE at 20.31% in the control group and 4.71% in the test group for patients with DM and CVD at day 210 is what I had seen from Don's, Dr Wong's and other presentation from about February of 2015. This is of course the 77% relative risk reduction achieved in just 6 months!

So the science is in excellent shape (to say the least) and progress is moving well. As is well known I have become frustrated with Don lately because of things like the Richmond Club. This of course relates to how this company communicates to the public. This filing is a clear demonstration of the integrity of RVX and the potential blockbuster poer of rvx-208.

Also, I would have expected some communications with the final closing of the Hepalink deal in the media such as the Globe and Mail's Report on Business and other high profile press.

Regarding the steering committee, for some reason I seem to get the idea that Dr Stephen Nicholls is not very positive toward RVX??? He is a scientist and at the end of the day he will influence good science to take place. Therefore, it is probably a very good thing to have once's chief critic on the steering committee AND also to have a committee of such high profille scientists.

It is indeed exciting times for RVX. I hope that analysts will take the time to read this filing in detail. I also wish that RVX would leverage their achievements to the media.

This filing may lead to BP beginning to re-examine RVX and get it while theprice is right and it may help with progress on new regional deals.

Anyway, just thinking out loud again.

Thanks very much for your efforts BDAZ. I was getting discouraged but it all looks good.

GLTA DYODD

Cheers

Toinv